Is Cryoport, Inc. (CYRX) a Buy, Sell, or Hold?
NASDAQ : CYRX
Cryoport, Inc. — News
$14.71 USD
-$0.54 (-3.54%)
- Volume
- 633.43K
- Average Volume
- 810.2K
- Market Capitalization
- $741.42M
- P/E Ratio
- -17.94
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $16.89
- Year Low
- $7.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.08
| Source | Headline |
|---|---|
|
CryoPort Q2 Earnings Call Highlights
CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million. marketbeat.com - 2026-08-06 21:04:51 |
|
CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago. zacks.com - 2026-08-06 18:41:04 |
|
Cryoport Reports Second Quarter 2026 Financial Results
Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026. prnewswire.com - 2026-08-06 16:05:00 |
|
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close. prnewswire.com - 2026-07-23 08:00:00 |
|
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310). prnewswire.com - 2026-06-25 08:00:00 |
